© 2004 European Society of Cardiology
Erythropoietin improves left ventricular function and coronary flow in an experimental model of ischemia-reperfusion injury*
a Department of Cardiology, University Hospital Groningen Groningen, The Netherlands
b Department of Pathology, University Hospital Groningen Groningen, The Netherlands
c Department of Clinical Pharmacology, University of Groningen A. Deusinglaan 1, 9713 AV, Groningen, The Netherlands
* Corresponding author. Tel.: +31-50-3632810; Fax: +31-50-3632812 E-mail address: w.h.van.gilst{at}med.rug.nl
 |
Abstract |
|---|
Background: Recent studies show that erythropoietin (EPO) plays a protective role in brain ischemia. In this condition, administration of EPO protects neurons from ischemic damage. Recently, it has been shown that in patients with chronic heart failure (CHF), EPO treatment improved cardiac function. In the present study we assessed the role of EPO and EPO-receptor (EPO-R) in the heart.
Methods and results: We studied the presence and functionality of the EPO-R in isolated rat hearts in the Langendorff set-up. Hearts were perfused for 20 min with 10 U/ml EPO or vehicle. Immunohistochemistry revealed the presence of the EPO-R on endothelial cells, fibroblasts and to a lesser extent cardiomyocytes. Furthermore, perfusion with EPO resulted in a 50% increase in the phosphorylated MAP kinases p42/p44. To evaluate the protective role of EPO in cardiac ischemia, we performed low-flow (0.6 ml/min) ischemia/reperfusion experiments in isolated rat hearts. Administration of EPO (10 U/ml) reduced the cellular damage by 56% (P<0.05) during reperfusion, diminished apoptosis by 15% (P<0.05) and resulted in a significantly improved recovery of left ventricular pressure (P=0.02) and coronary flow (P=0.01).
Conclusion: The present data suggest that a functional EPO-R is present in rat adult cardiac tissue and that exogenous EPO administration improves cardiac function after ischemia/reperfusion injury.
Key Words: Erythropoietin • Ischemia • Reperfusion • Receptors
Received September 13, 2003; Revised February 3, 2004; Accepted March 3, 2004
The authors Peter van der Meer and Erik Lipsic contributed equally to this work.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. Mihov, N. Bogdanov, B. Grenacher, M. Gassmann, G. Zund, A. Bogdanova, and R. Tavakoli Erythropoietin protects from reperfusion-induced myocardial injury by enhancing coronary endothelial nitric oxide production Eur. J. Cardiothorac. Surg., May 1, 2009; 35(5): 839 - 846. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. D. Vaziri and X. J. Zhou Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease Nephrol. Dial. Transplant., April 1, 2009; 24(4): 1082 - 1088. [Full Text] [PDF]
|
|
|
|
 |
|
 E. Lipsic, B. D. Westenbrink, P. van der Meer, P. van der Harst, A. A. Voors, D. J. van Veldhuisen, R. G. Schoemaker, and W. H. van Gilst Low-dose erythropoietin improves cardiac function in experimental heart failure without increasing haematocrit Eur J Heart Fail, January 1, 2008; 10(1): 22 - 29. [Abstract] [Full Text] [PDF]
|
|